Effects of carbamazepine and metabolites on IL-2, IL-5, IL-6, IL-10 and IFN-γ secretion in epileptic patients: the influence of co-medication.

Journal Title: Pharmacological Reports - Year 2011, Vol 63, Issue 1

Abstract

Carbamazepine is a widely used anticonvulsive agent. Its metabolic pathway leads not only to the major active metabolite, carbamazepine-10,11-epoxide, but also to minor terminal metabolites such as iminostilbene and acridine. Carbamazepine is usually well-tolerated, but it may lead to rare, but serious, hypersensitive reactions associated with hypereosinophilia. The mechanisms of hypersensitivity reactions to carbamazepine are still largely unknown, and the implications of the cell-mediated immune response (Th1 pathway) or the humoral immune response (Th2 pathway) are still not understood in these reactions. It is also unclear whether the parent drug or its subsequent metabolites are the primary trigger agent. In our study, we performed ex vivo experiments to evaluate the stimulation of cytokine secretion by carbamazepine, carbamazepine-10,11-epoxide, iminostilbene and acridine. IL-5, IL-6 and IL-10 were quantified as markers of the Th2 pathway, and IL-2 and IFN-γ were used as markers of the Th1 pathway. Blood samples (n=24) were obtained from epileptic patients routinely treated with carbamazepine alone or co-treated with lamotrigine or valproate. The concentrations of cytokines in the plasma were determined before and after 3 h stimulation with drugs. We found a significantly positive effect of co-treatment with valproate on the basal level of IL-5 (p<0.01) and IL-10 (p<0.05). IL-5 production increased only in blood stimulated with a high level of acridine (33 μM), whereas IL-6 production was less specifically stimulated (p<0.05). Because IL-5 is the most potent stimulating factor of the eosinophils, we suggest that the potential helper effect of valproate and acridine can lead to hypersensitive reactions to carbamazepine in the context of the humoral immune response.

Authors and Affiliations

Olivier Mathieu, Marie-Christine Picot, Philippe Gelisse, Hélène Breton, Pascal Demoly, Dominique Hillaire-Buys

Keywords

Related Articles

Monocyte-suppressing effect of high-dose metformin in fenofibrate-treated patients with impaired glucose tolerance.

Background: Fibrates were found to reduce cytokine release and low-grade inflammation in patients with impaired glucose tolerance. The aim of this study was to investigate whether these effects of fibrates may be potenti...

Role of vinpocetine in cerebrovascular diseases.

A cerebrovascular accident, or stroke, is defined as the abrupt onset of a neurological deficit, which can be due to ischemia. Cerebral ischemia is caused by a reduction in blood flow that thereby decreases cerebral meta...

Effect of gas phase and particulate phase of cigarette smoke on salivary antioxidants. What can be the role of vitamin C and pyridoxine?

The effect of smoking is in our days a serious global public health problem of major concern. Incidence of oral squamous cell carcinoma (SCC) in cigarette smokers is four to seven times higher than in nonsmokers. There i...

Influence of cimetidine on the anticonvulsant activity of conventional antiepileptic drugs against pentetrazole-induced seizures in mice.

The aim of this study was to evaluate the effects of acute (1 day) andchronic (7 days) administrations of cimetidine, an H(2) histamine receptor antagonist, on the protective activity of conventional antiepileptic drugs...

Anxiolytic effect of noscapine in mice.

The anxiety-related effects of noscapine were investigated using male Balb-c mice. Since noscapine-induced locomotion may alter the animals' activity level in the dark-light model, the anxiety-related effects of noscapin...

Download PDF file
  • EP ID EP129499
  • DOI -
  • Views 86
  • Downloads 0

How To Cite

Olivier Mathieu, Marie-Christine Picot, Philippe Gelisse, Hélène Breton, Pascal Demoly, Dominique Hillaire-Buys (2011). Effects of carbamazepine and metabolites on IL-2, IL-5, IL-6, IL-10 and IFN-γ secretion in epileptic patients: the influence of co-medication.. Pharmacological Reports, 63(1), 86-94. https://europub.co.uk/articles/-A-129499